Market Cap 136.28B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 7.47
Forward PE 7.83
Profit Margin 12.62%
Debt to Equity Ratio 0.69
Volume 63,098,100
Avg Vol 46,646,223
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 36%
Beta 0.57
Analysts Sell
Price Target $27.62

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
GreenEnergy2022
GreenEnergy2022 Jun. 23 at 12:49 PM
$ALT Could it be that $NVO won the bidding war over $PFE ?
0 · Reply
PaddyIce87
PaddyIce87 Jun. 23 at 12:14 PM
$SGMO It’s really cute how many thought Sandy’s most recent deadline for Fabry would be met … Although there is still a little bit of time, I have a feeling it will be met with the same verbiage as each and every time he moves another goalpost… Even when we have nice things ( $PFE ), we don’t .
1 · Reply
Wallst45
Wallst45 Jun. 23 at 12:07 PM
$ALT $PFE buyout yay 😁
0 · Reply
stockhawk11
stockhawk11 Jun. 23 at 12:04 PM
$ALT perhaps final negotiations taking place with $PFE Perhaps they want to take this to $10 before news
1 · Reply
TradetheMatrix
TradetheMatrix Jun. 23 at 11:14 AM
$PFE more need more. Love the dividend. Constant expansion. Great company, they are my #1 customer in my line of work.
0 · Reply
RocroBio
RocroBio Jun. 23 at 5:42 AM
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 23 at 1:51 AM
$MRK $AMGN $PFE $ESPR Doctor perspective on Esperions Bempedoic acid versus PCSK9 & other cholesterol lowering medications. Listen to the recording > https://x.com/sigmatrader9/status/1933255422221434882?t=2FC6LnkmqBWydJiFWeW6jw&s=19
0 · Reply
Wallst45
Wallst45 Jun. 22 at 11:36 PM
$ALT $PFE omg omg 😍
1 · Reply
RoutineMidnight5779
RoutineMidnight5779 Jun. 22 at 11:34 PM
$VXRT Pfizer $PFE should buyout Vaxart $VXRT
0 · Reply
stockhawk11
stockhawk11 Jun. 22 at 10:51 PM
$ALT PRESS RELEASE: Pfizer ( $PFE ) acquires Altimmune ( $ALT ) for 2.7 billion dollars!!!! Let’s gooo lol just kidding it’s coming tho!
6 · Reply
Latest News on PFE
The Dark Side Of Dividend Growth Investing

Jun 21, 2025, 8:05 AM EDT - 2 days ago

The Dark Side Of Dividend Growth Investing

ET LEG O T WBA WPC XIFR


I'm Buying Dividend Giants At Huge Discounts

Jun 20, 2025, 9:00 AM EDT - 2 days ago

I'm Buying Dividend Giants At Huge Discounts

ABBV BMY CVX OXY SHEL SLB TTE


Pfizer: An Offensive Play For A Bear Market

Jun 20, 2025, 4:41 AM EDT - 3 days ago

Pfizer: An Offensive Play For A Bear Market


Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare

Jun 10, 2025, 4:56 AM EDT - 13 days ago

Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare


Buy, Sell, Or Hold PFE Stock At $23?

Jun 3, 2025, 10:00 AM EDT - 19 days ago

Buy, Sell, Or Hold PFE Stock At $23?


Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline

May 27, 2025, 10:12 PM EDT - 26 days ago

Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline


Stocks With the Highest Dividend Yields in the S&P 500

May 25, 2025, 5:08 PM EDT - 4 weeks ago

Stocks With the Highest Dividend Yields in the S&P 500

BEN DOW VZ WBA


Pfizer Looks Like A Great Play At Current Valuations

May 21, 2025, 12:20 PM EDT - 4 weeks ago

Pfizer Looks Like A Great Play At Current Valuations


Pfizer Pacing for 4th Day of Gains

May 20, 2025, 1:35 PM EDT - 4 weeks ago

Pfizer Pacing for 4th Day of Gains


Pfizer Thinks Bigger With 3SBio Deal

May 20, 2025, 11:46 AM EDT - 4 weeks ago

Pfizer Thinks Bigger With 3SBio Deal


Pfizer strikes deal with China's 3SBio to license cancer drug

May 20, 2025, 8:51 AM EDT - 4 weeks ago

Pfizer strikes deal with China's 3SBio to license cancer drug


Pfizer Enters into Exclusive Licensing Agreement with 3SBio

May 19, 2025, 8:00 PM EDT - 4 weeks ago

Pfizer Enters into Exclusive Licensing Agreement with 3SBio


Buy These 2 Beaten Down Stocks Now Before They Rally

May 19, 2025, 1:00 PM EDT - 4 weeks ago

Buy These 2 Beaten Down Stocks Now Before They Rally

AAT ARE BMY


GreenEnergy2022
GreenEnergy2022 Jun. 23 at 12:49 PM
$ALT Could it be that $NVO won the bidding war over $PFE ?
0 · Reply
PaddyIce87
PaddyIce87 Jun. 23 at 12:14 PM
$SGMO It’s really cute how many thought Sandy’s most recent deadline for Fabry would be met … Although there is still a little bit of time, I have a feeling it will be met with the same verbiage as each and every time he moves another goalpost… Even when we have nice things ( $PFE ), we don’t .
1 · Reply
Wallst45
Wallst45 Jun. 23 at 12:07 PM
$ALT $PFE buyout yay 😁
0 · Reply
stockhawk11
stockhawk11 Jun. 23 at 12:04 PM
$ALT perhaps final negotiations taking place with $PFE Perhaps they want to take this to $10 before news
1 · Reply
TradetheMatrix
TradetheMatrix Jun. 23 at 11:14 AM
$PFE more need more. Love the dividend. Constant expansion. Great company, they are my #1 customer in my line of work.
0 · Reply
RocroBio
RocroBio Jun. 23 at 5:42 AM
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 23 at 1:51 AM
$MRK $AMGN $PFE $ESPR Doctor perspective on Esperions Bempedoic acid versus PCSK9 & other cholesterol lowering medications. Listen to the recording > https://x.com/sigmatrader9/status/1933255422221434882?t=2FC6LnkmqBWydJiFWeW6jw&s=19
0 · Reply
Wallst45
Wallst45 Jun. 22 at 11:36 PM
$ALT $PFE omg omg 😍
1 · Reply
RoutineMidnight5779
RoutineMidnight5779 Jun. 22 at 11:34 PM
$VXRT Pfizer $PFE should buyout Vaxart $VXRT
0 · Reply
stockhawk11
stockhawk11 Jun. 22 at 10:51 PM
$ALT PRESS RELEASE: Pfizer ( $PFE ) acquires Altimmune ( $ALT ) for 2.7 billion dollars!!!! Let’s gooo lol just kidding it’s coming tho!
6 · Reply
BioTechChap
BioTechChap Jun. 22 at 6:18 PM
$ALT $MDGL $PFE $VKTX $XBI Dude, stop making such a big fuss of an underpowered subgroup analysis. You must be the most muted account on ST all time! Get some peace, get a life, unsubscribe from ALT board. We’ll all be just fine and happy.
1 · Reply
BioRich
BioRich Jun. 22 at 6:09 PM
$ALT $XBI $VKTX $MDGL $PFE @Wallst45 No, this is bad for $ALT. Here's what's worse. $ALT has the data. They did the MRI-based analysis on the Placebo arm at the same time as they did the Pemvi arms and chose to never present it. It's been 570 Days since the initial Obesity P2 data was released and this is still withheld? This is a HUGE issue for $ALT. SEC/FDA type implications. Material information withheld. That's most definitely not a good thing.
1 · Reply
posyche
posyche Jun. 22 at 6:03 PM
$HIMX $SOFI $PFE oil futures are currently down 15% from fri. 73.80ish+, to today 62.60ish. down 11 points. theory still holds that the market will soar tomorrow....
2 · Reply
BioRich
BioRich Jun. 22 at 5:46 PM
$ALT $XBI $VKTX $MDGL $PFE Breaking News!!! The average weight loss in the Placebo Arm of $ALT's "Best in Class" lean mass data sub study was ~18.2 lbs!!! ALT has NEVER presented the body composition data on this arm so their 21.9% claims were never able to put into perspective. Why does ALT withhold this data? 1) Are they afraid it will prove that the 21.9% they are claiming isn't as impressive as they would like it to appear? 2) Are they afraid that previous concerns raised regarding the effects of Diet and Exercise (Lifestyle Interventions) on $ALT's Obesity P2 trial results would be founded? 3) Are they afraid that the Pemvi arms of the trial actually showed worse lean mass preservation than the Placebo arm? Folks, argue all you want. Without this information, no claim $ALT makes with regards to lean mass matters. There's no context and they've withheld information. Let that sink in before you bash people trying to help you. Follow/Subscribe for more suggestions and perspective. Cheers!
4 · Reply
Kilarck
Kilarck Jun. 22 at 5:45 PM
$PFE https://talkmarkets.com/content/stocks--equities/galectin-therapeutics-is-undervalued-and-with-short-squeeze-underway?post=504960 This will be on every BP radar after the get a special voucher from the FDA. Dr. Ben Carson is on the BoD. First clinical effect in cirrhosis. Huge squeeze underway.
0 · Reply
ValuePlayRunners
ValuePlayRunners Jun. 22 at 1:19 PM
$ALT Statins are junk...sure, needed for some with genetic issues but it's the cotton candy for most prescribing doctors, because those prescribing often do not really understand the liver. Cholesterol is not the smoking gun in heart disease like those docs prescribing statins want you to believe. The data hasn't really ever supported it but that sector gotta be the largest cumulative revenue generating out of any in the drug. I mean Lipitor alone has generated over $170 BILLION for $PFE. Just insane. Pemi will take a chunck out of the heart disease market for sure without the God awful side effects of statins, beta blockers, BP meds and so on $ALT remember, a pipeline in 1 drug.
1 · Reply
GreenEnergy2022
GreenEnergy2022 Jun. 22 at 11:39 AM
$ALT Data presented at ADA, this looks very very good actually! Triglycerides Total Cholesterol LDL. I think just a question about time before someone scoop up this company, maybe: $AZN $PFE $NVO $GILD
0 · Reply
BioRich
BioRich Jun. 22 at 6:15 AM
$ALT Remember this? Remember how we asked for the Placebo arm data for Lean Mass Ratio and we were told it didn't matter because Placebo was ~2% in the full trial? Turns out this glaring omission was because the Placebo arm in the Lean Mass Subgroup had an 8.2% weight loss. This suggests that the lean mass data from the Placebo (Control) group would have produced relevant data. That relevant data would have likely diluted ALT's Lean Mass claims and not be a talking point (likely showing statistical INsignificance). Maybe I'm missing something here. Can any Bulls help me out? $XBI $VKTX $MDGL $PFE
5 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 22 at 3:40 AM
$NUVB this article should be essential reading for all $NUVB bulls & bears. Particularly this note about the NCCN guidelines being changed for frontline. This is HUGE and the reason why Ibtrozi can crush the current ROS1 drugs. We know $BMY and $PFE won’t buy them because of antitrust concerns in this small space (2% of all NSCLC = 3K cases per year per my earlier post). Full disclaimer: this is not financial advice but I own $20K of NUVB and am buying dips. GLL 👍 ☘️ 🐂 https://www.fiercepharma.com/pharma/david-hung-nuvation-bio-wins-fda-approval-ibtrozi-challenge-pfizer-bms-and-roche-lung-cancer
1 · Reply
posyche
posyche Jun. 22 at 12:41 AM
$HIMX $SOFI $PFE likely a major plus for the stock market, as there is no major demonstrated threat from Iran. will there be instances?, yes, likely...but nothing that theoretically would affect the markets. only card is oil. as well, this may spur peace talks with Hamas, and Hezbollah, as they have no support. market up big on Monday. that's my opinion....
3 · Reply
ValuePlayRunners
ValuePlayRunners Jun. 21 at 11:38 PM
$ALT I believe it's round #2 in $PFE history of having a blockbuster drug. Round 1 was VIAGRA. A drug initially purposed for Angina & High Blood Pressure in the 80's. Repurposed an approved 1998 for first oral pill for ED. Blockbuster drug is an understatement. Generating somewhere between $25 - $70 Billion in revenue since approved. Pemi could also be a blockbuster drug IF Mash data comes in BIC etc. $ALT pemi also has many potential indications besides MASH & Obesity. Some have referenced in the ALT thread cardiac naturally...then ED, andropause/menopause/hormone issues...sleep support ...anti-aging medicine and more. Can't experience health when the liver is not working properly and it goes way beyond the silly liver enzyme test most get at their PCP. Buy out ALT by PFE - yes!
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jun. 21 at 10:46 PM
$SLS Phase 3, FDA Registrational Trial Results - Worth Literally $10B + to Big Pharma Will BE Announced - ANY DAY NOW. GPs, an Immunotherapy for AML Remission Maintenance - 5 years in the Making and Imminent. - at the ASM CEO Disclosed patients on GPs are Living 3+ Years - vs Dr's who Treat Actual P3 Control Patients Stating OS is Only 6-8 months with Best Available Treatments. Cash Runway into Q3, 2026 and More Cash Coming. This Short Manipulated $154M equity offers the Investment Opportunity of a Lifetime. Now up to 59 Institutional Funds Invested, holding 34% of FLOAT, vs 38 funds w 8% - Q3 2024. - INSIDERS PURCHASING on the Open Market - 99.9 to .01 CALL to Put Ratio. $PFE $NVS $LLY
0 · Reply